# Immatics Reports 32% Confirmed Response Rate for IMA402 in PRAME-High Melanoma > Immatics reported a 32% confirmed response rate for IMA402 in PRAME-high melanoma and 41% across tumors for IMA203CD8, with no Grade 5 safety events. - Published: 2026-10-24T06:58:39+00:00 - Section: Research & Clinical Trials - Author: News Desk - URL: https://newsforagent.com/news/2026-10-24/immatics-ima402-prame-melanoma-response - Source: [TradingView](https://www.tradingview.com/news/tradingview:206538f11fca5:0-immatics-n-v-imtx-reports-phase-1-prame-data-with-32-corr-in-melanoma/) ## Key takeaways - Immatics reported a 32% confirmed objective response rate for IMA402 in advanced melanoma patients with high PRAME expression. - IMA203CD8 cell therapy showed a 41% confirmed response rate across tumors and 55% in gynecologic cancers at clinically relevant doses. - No Grade 5 events occurred, and cytokine release syndrome was mostly low-grade across the reported Phase 1 data. Immatics reported a 32% confirmed objective response rate for its IMA402 bispecific in advanced melanoma patients with high PRAME expression, alongside a 41% confirmed response rate for its IMA203CD8 cell therapy across tumor types. The Phase 1 data were presented at the 2026 ESMO Annual Meeting, [TradingView](https://www.tradingview.com/news/tradingview:206538f11fca5:0-immatics-n-v-imtx-reports-phase-1-prame-data-with-32-corr-in-melanoma/) reported. ## Immatics' IMA402 and IMA203CD8 Phase 1 Results Immatics is a clinical-stage biopharmaceutical company developing PRAME-directed TCR-based immunotherapies, including autologous cell therapies and TCR bispecifics, for patients with PRAME-positive solid tumors such as melanoma, ovarian, lung, and head and neck cancers, according to company records. IMA402 achieved a 32% confirmed objective response rate, a 12.5-month median duration of response and a 91% one-year overall survival rate in advanced melanoma patients with high PRAME expression. Across all PRAME levels, IMA402 showed a 25% confirmed response rate in 40 patients. The bispecific's clinical profile supports development across melanoma, gynecologic cancers and lung cancer in earlier and later treatment lines, supported by liquid biopsy-based PRAME testing. IMA203CD8 demonstrated a 41% confirmed response rate in 87 patients across multiple tumor types. At clinically relevant dose levels in patients with advanced, heavily pretreated gynecologic cancers, the cell therapy showed a 55% confirmed response rate in 20 patients with a median duration of response of 8.4 months. Safety was manageable, with no Grade 5 events and cytokine release syndrome mostly low-grade. [FinanzNachrichten.de](https://www.finanznachrichten.de/nachrichten-2026-10/69925433-immatics-presents-clinical-activity-of-ima402-prame-bispecific-and-ima203cd8-prame-cell-therapy-across-advanced-solid-tumors-in-two-oral-presentations-399.htm) reported that Immatics presented the updated clinical data for IMA402 and IMA203CD8 in two oral presentations at the 2026 ESMO Annual Meeting, and that the company plans further development across solid tumors. ## Immatics' PRAME Franchise Development Path Immatics' next steps include combinations and targeted cohorts, the company said. The company reported anzu-cel (IMA203) Phase 1b results at ASCO 2026 demonstrating a 56% confirmed ORR with a 14.6-month median duration of response in 33 heavily pretreated metastatic melanoma patients, supporting the registrational SUPRAME Phase 3 program and a planned H1 2027 BLA submission, according to akta.pro [company records](https://akta.pro/company-data). In May 2026, Immatics presented updated Phase 1 data at ASCO 2026 showing IMA203CD8 achieved a 63% ORR (50% confirmed, 4 complete responses) in heavily pretreated gynecologic cancers and a 67% ORR in synovial sarcoma. The same month, Immatics entered a strategic collaboration with Cellular Origins to integrate the Constellation automated mobile robotic manufacturing platform into its cell-therapy production, targeting scalable, cost-effective supply for the upcoming PRAME solid-tumor commercial launch. ## Immatics' Recent Company Milestones In October 2026, certain options of Immatics were subject to a lock-up agreement ending on 24-OCT-2026, covering 61 days from 24-AUG-2026, MarketScreener reported. In September 2023, Immatics and Moderna entered a strategic research and development collaboration spanning bispecifics, cell therapy and cancer vaccines, according to company records. ## What Comes Next for Immatics Immatics said its next steps include combinations and targeted cohorts. The company has a planned H1 2027 BLA submission for anzu-cel (IMA203), according to company records. ## Companies in this story - [immatics biotechnologies company profile](https://akta.pro/company-profiles/0003tdt/immatics-biotechnologies) · website: https://immatics.com --- News for Agent · https://newsforagent.com/llms.txt